8-K: Microbot Medical Study Published in Leading Journal

Microbot Medical announced the publication of its LIBERTY ACCESS PVI Pivotal Study in the Journal of Vascular and Interventional Radiology, a significant validation for its robotic system.

Summary

• Microbot Medical Inc. announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR).
• The article, titled "In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study," details the LIBERTY ACCESS PVI Pivotal Study.
• Dr. Francois Cornelis, a leading interventional radiologist, was the first author and Lead Principal Investigator for the study.
• Publication in a peer-reviewed journal signifies rigorous vetting of the study's methodology and data by independent experts.
• The ACCESS-PVI study was completed in 2025 and initially presented at the Society of Interventional Radiology (SIR) annual meeting in April 2025.
• The LIBERTY system received U.S. Food and Drug Administration (FDA) clearance in September 2025 for peripheral endovascular procedures.
• LIBERTY is described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
• The company commenced a limited market release of the LIBERTY system in late 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as peer-reviewed publication in a leading journal significantly de-risks the commercialization pathway and enhances the credibility of the LIBERTY system, positioning the company well for its upcoming full market release.

Positives

• Publication in the Journal of Vascular and Interventional Radiology (JVIR), a premier peer-reviewed journal, validates the quality and impact of the LIBERTY ACCESS PVI Pivotal Study.
• Peer-reviewed publication is considered the gold standard for clinical validation, enhancing credibility and trust in the LIBERTY system.
• The LIBERTY system received U.S. FDA clearance in September 2025 for peripheral endovascular procedures.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, offering unique advantages.
• The system is designed to provide precise vascular navigation and aims to reduce radiation exposure and physical strain for medical professionals.
• The company is focused on expanding evidence-based data to support broader commercial adoption.

Risks

• Market conditions.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System.
• Risks in the development of future versions of or applications for the system.
• Uncertainty in the results of regulatory pathways and regulatory approvals.
• Uncertainty resulting from political, social, and geopolitical conditions, particularly changes in personnel or processes at the FDA.
• Announcements of tariffs on imports into the U.S.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Maintenance of intellectual property rights.

Future Outlook

The company remains focused on expanding evidence-based data to support broader commercial adoption of the LIBERTY system. It plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to deepen market adoption. Management looks forward to generating more clinical evidence to foster appreciation for the system's benefits.

Management Comments

• "We are very pleased by the publication of the ACCESS-PVI results in JVIR, a leading voice in the field. This is a recognition that speaks to the quality and impact of the study." Juan Diaz-Cartelle, Chief Medical Officer.
• "We would like to thank all the co-authors and we are looking forward to generating more clinical evidence that would foster appreciation for the benefits of the LIBERTY system." Juan Diaz-Cartelle, Chief Medical Officer.

Industry Context

StockSavvy.ai notes that the publication of clinical study results in a premier peer-reviewed journal like JVIR is a critical step for medical device companies. It provides independent validation of the technology, which is essential for building trust among interventional radiologists and driving commercial adoption. In the rapidly evolving field of robotic-assisted surgery, such validation helps differentiate Microbot Medical's LIBERTY system from competitors and reinforces its position as an innovator in endovascular procedures.

Stakeholder Impact

• Shareholders: Positive impact due to increased validation and potential for broader commercial adoption, which could lead to revenue growth.
• Medical Professionals (Interventional Radiologists): Provides evidence-based data supporting the use of the LIBERTY system, potentially reducing radiation exposure and physical strain.
• Patients: Potential for more precise and safer endovascular procedures.
• Employees: Positive impact from company growth and successful product validation.

Next Steps

• Generate more clinical evidence to foster appreciation for the benefits of the LIBERTY system.
• Full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026.
• Deepen market adoption of the LIBERTY system.

Key Dates

Recommendation

The publication of the pivotal study in a top-tier peer-reviewed journal is a significant de-risking event for Microbot Medical's LIBERTY system, following its FDA clearance. This independent validation is crucial for market acceptance and commercial success in the medical device industry. With a full market release planned soon, this news provides strong fundamental support for future growth and adoption, making it a compelling "strong buy" for investors looking for exposure to innovative robotic medical technologies.

Keywords

Endovascular Robotic System, LIBERTY System, Microbot Medical, Peripheral Vascular Interventions, FDA Clearance, Medical Device, Robotics, Interventional Radiology, Peer-Reviewed Publication, ACCESS PVI Study, Healthcare Technology